A Seven-lncRNA Signature for Predicting Prognosis in Breast Carcinoma

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35116701

Authors

Min Xu

Ziyan Chen

Bangyi Lin

Sina Zhang

Jinmiao Qu

Affiliations

Soon will be listed here.

Abstract

Background: Long non-coding RNAs (lncRNAs) play an important part in tumorigenesis and cancer metastasis and can serve as a potential biosignature for cancer prognosis. However, the use of lncRNA signatures to predict survival in breast carcinoma is yet unreported.

Methods: The lncRNA expression profiles and homologous clinical data of 913 breast carcinoma samples from the Cancer Genome Atlas (TCGA), were analyzed to obtain 2,547 differentially expressed lncRNAs. Univariate Cox proportional risk regression was applied to both the training and testing datasets to screen the common prognostic lncRNAs. Potential prognostic LncRNAs were screened by multivariate Cox proportional risk regression in the training data set of the selected LncRNAs.

Results: Seven lncRNAs (LINC02037, MAPT-AS1, RP1-37C10.3, RP11-344E13.4, RP11-454P21.1, RP11-616M22.1, SPACA6P-AS) were prominently associated with overall survival. Kaplan-Meier analysis and receiver operating characteristic (ROC) curves indicated that these indicators were sensitive and specific for survival prediction. The areas under the ROC curve of the seven-lncRNA signature in predicting 3- and 5-year survival rates were 0.771 and 0.780 respectively in the combined cohort. Furthermore, enrichment analysis revealed that these seven lncRNAs might participate multiple pathways related to tumorigenesis and prognosis.

Conclusions: The proposed seven-lncRNA signature could serve as a latent prognostic biomarker for survival prediction in patients with breast carcinoma.

Citing Articles

Innovation in CRC Research: Targeting SPACA6P-AS for Progression.

Ma T, Jin Y, Wang S, Hu H, Wang M, Yan G J Biochem Mol Toxicol. 2024; 38(12):e70039.

PMID: 39655708 PMC: 11629451. DOI: 10.1002/jbt.70039.

SPACA6P-AS: a trailblazer in breast cancer pathobiology and therapeutics.

Feng W, Jiang Y, Zeng L, Ouyang Y, Li H, Tang Y Cell Biol Toxicol. 2024; 40(1):49.

PMID: 38922500 PMC: 11208203. DOI: 10.1007/s10565-024-09870-9.

Identification of potential biomarkers and pathways for asthenozoospermia by bioinformatics analysis and experiments.

Lu H, Zhao L, Wang A, Ruan H, Chen X, Li Y Front Endocrinol (Lausanne). 2024; 15:1373774.

PMID: 38863929 PMC: 11165088. DOI: 10.3389/fendo.2024.1373774.

A novel PD-1/PD-L1 pathway-related seven-gene signature for the development and validation of the prognosis prediction model for breast cancer.

Zhang P, Yang J, Zhong X, Selistre-de-Araujo H, Boussios S, Ma Y Transl Cancer Res. 2024; 13(3):1554-1566.

PMID: 38617520 PMC: 11009795. DOI: 10.21037/tcr-23-2270.

Crosstalk between Long Non-Coding RNA and Spliceosomal microRNA as a Novel Biomarker for Cancer.

Arafat M, Sperling R Noncoding RNA. 2023; 9(4).

PMID: 37624034 PMC: 10459839. DOI: 10.3390/ncrna9040042.

References

ODonovan P, Livingston D . BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010; 31(6):961-7. DOI: 10.1093/carcin/bgq069. View

Colditz G, Bohlke K . Priorities for the primary prevention of breast cancer. CA Cancer J Clin. 2014; 64(3):186-94. DOI: 10.3322/caac.21225. View

King T, Lyman J, Gonen M, Voci A, Brot M, Boafo C . Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. J Clin Oncol. 2016; 34(20):2359-65. PMC: 4981976. DOI: 10.1200/JCO.2015.63.1960. View

Gyorffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L . Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2015; 17:11. PMC: 4307898. DOI: 10.1186/s13058-015-0514-2. View

Li J, Wang W, Xia P, Wan L, Zhang L, Yu L . Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer. Int J Cancer. 2018; 143(9):2150-2160. PMC: 6519083. DOI: 10.1002/ijc.31573. View

Scheffner M, Werness B, Huibregtse J, Levine A, Howley P . The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63(6):1129-36. DOI: 10.1016/0092-8674(90)90409-8. View

Ma H, Hao Y, Dong X, Gong Q, Chen J, Zhang J . Molecular mechanisms and function prediction of long noncoding RNA. ScientificWorldJournal. 2013; 2012:541786. PMC: 3540756. DOI: 10.1100/2012/541786. View

Langfelder P, Horvath S . WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008; 9:559. PMC: 2631488. DOI: 10.1186/1471-2105-9-559. View

Yang Y, Qian J, Xiang Y, Chen Y, Qu J . The prognostic value of long noncoding RNA HOTTIP on clinical outcomes in breast cancer. Oncotarget. 2016; 8(4):6833-6844. PMC: 5351673. DOI: 10.18632/oncotarget.14304. View

10.

Zhou M, Xu W, Yue X, Zhao H, Wang Z, Shi H . Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma. Oncotarget. 2016; 7(20):29720-38. PMC: 5045428. DOI: 10.18632/oncotarget.8825. View

11.

Harryvan T, Tushuizen M . A Young Patient With Diabetes and Liver Tumors. Gastroenterology. 2018; 155(1):25-26. DOI: 10.1053/j.gastro.2017.12.031. View

12.

Arshi A, Sharifi F, Khorramian Ghahfarokhi M, Faghih Z, Doosti A, Ostovari S . Expression Analysis of MALAT1, GAS5, SRA, and NEAT1 lncRNAs in Breast Cancer Tissues from Young Women and Women over 45 Years of Age. Mol Ther Nucleic Acids. 2018; 12:751-757. PMC: 6108071. DOI: 10.1016/j.omtn.2018.07.014. View

13.

Verhagen F, Stigter E, Pras-Raves M, Burgering B, Imhof S, Radstake T . Aqueous Humor Analysis Identifies Higher Branched Chain Amino Acid Metabolism as a Marker for Human Leukocyte Antigen-B27 Acute Anterior Uveitis and Disease Activity. Am J Ophthalmol. 2018; 198:97-110. DOI: 10.1016/j.ajo.2018.10.004. View

14.

French C, Tambini C, Thacker J . Identification of functional domains in the RAD51L2 (RAD51C) protein and its requirement for gene conversion. J Biol Chem. 2003; 278(46):45445-50. DOI: 10.1074/jbc.M308621200. View

15.

Chen X, You Z, Yan G, Gong D . IRWRLDA: improved random walk with restart for lncRNA-disease association prediction. Oncotarget. 2016; 7(36):57919-57931. PMC: 5295400. DOI: 10.18632/oncotarget.11141. View

16.

Mirchandani K, DAndrea A . The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair. Exp Cell Res. 2006; 312(14):2647-53. DOI: 10.1016/j.yexcr.2006.06.014. View

17.

Zhou M, Zhao H, Wang Z, Cheng L, Yang L, Shi H . Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. J Exp Clin Cancer Res. 2015; 34:102. PMC: 4567800. DOI: 10.1186/s13046-015-0219-5. View

18.

Liao Q, Liu C, Yuan X, Kang S, Miao R, Xiao H . Large-scale prediction of long non-coding RNA functions in a coding-non-coding gene co-expression network. Nucleic Acids Res. 2011; 39(9):3864-78. PMC: 3089475. DOI: 10.1093/nar/gkq1348. View

19.

Sorensen K, Thomassen M, Tan Q, Bak M, Cold S, Burton M . Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers. Breast Cancer Res. 2015; 17:55. PMC: 4416310. DOI: 10.1186/s13058-015-0557-4. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View